Responses
Clinical and epidemiological research
Extended report
A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)
Compose a Response to This Article
Other responses
No responses have been published for this article.